Some say older patients are not being offered the same access to cancer care as younger patients.
A population-based study found survival benefit for metastatic renal cell carcinoma correlated with shift from cytokines to targeted therapies.
Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.
Pivotal phase 3 trials show promising top-line findings for patients with metastatic renal cell carcinoma.
From Oncology Nurse Advisor
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges
- ASCO Updates Metastatic Lung Cancer Therapy Guideline to Include Targeted Agents, Early Palliative Care
- Association of 21-Gene Recurrence Score Assay, Chemo in Early-stage Breast Cancer
- Sonography, MRI Comparable for Cervical Cancer Staging
- In Cutaneous Melanoma, Early Sentinel-Node Biopsy Associated with Poorer Survival
- Molecular Profiles Can be Used for Early Detection for Aggressive Prostate Cancer
- Thyroid Carcinoma Treatment Regimens
- Combining Aromatase Inhibitors, Bisphosphonates May Benefit Women With Breast Cancer
- Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
- Better Preoperative Coordination of Care Needed for Patients With Lung Cancer
- New Study Suggests Older Adults Not More Likely to Refuse Cancer Treatment
- Platinum-Based Chemo for Bladder Cancer Linked With Increased Thromboembolism Risk
- Immune Response to Chemo Improves PFS in Colorectal Cancer Liver Metastases
- African American Men With PCa Produce Less PSA Despite Larger Prostates
- Imetelstat Active in Myelofibrosis, But May Cause Myelosuppression
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|